C
Corteria Pharmaceuticals
Develops first-in-class drugs in heart failure subpopulations
About Corteria Pharmaceuticals
Corteria Pharmaceuticals is a startup that specializes in the development of innovative therapies for the treatment of heart failure and related conditions. Established in 2021, the company operates in the pharmaceutical industry, focusing on conditions with high unmet medical needs, such as heart failure, sarcopenia (muscle loss), and obesity.
The company's business model revolves around the development of first-in-class drugs. They use advanced methods to stratify patients, which means they categorize patients based on certain characteristics, to identify those who will benefit the most from their treatments. This approach is based on a deep understanding of disease biology and human evidence.
Corteria's primary focus is on worsening and acute heart failure, right heart failure, and sarcopenia related to aging and obesity. With over 60 million patients worldwide, heart failure is a growing concern due to factors like an aging population, increased diabetes incidence, and non-fatal heart attacks.
The company's revenue comes from the sale of these innovative drugs. They are currently developing a drug, COR-1167, which has shown promising results in reducing cardiac pressures and improving cardiac function in animal models.
In summary, Corteria Pharmaceuticals is a promising startup in the pharmaceutical industry, developing innovative therapies for heart failure and related conditions. Their patient-centric approach and focus on unmet medical needs position them well in a growing market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Paris, France
- Employees
- 25
- Open positions
- 3
- Dealroom signal
- 90.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, radar de l'innovation, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2023 | $72M | $286M | Omnes Capital · Fountain Healthcare Partners · Kurma Partners · OrbiMed | ↗ |
| SEEDOther financing | Dec 2021 | $13M | $53M | Omnes Capital · V-Bio Ventures · Kurma Partners · Invivo Partners | — |
Growth signals
Latest recorded traffic for Corteria Pharmaceuticals is 2.6K monthly website visits, up 202.3% over the last three months. Corteria Pharmaceuticals's team grew 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Omnes Capital
V-Bio Ventures
Kurma Partners
Invivo Partners
Series A3 investors entered at this stage
OrbiMed
Jeito Capital
Fountain Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Corteria Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Corteria Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.